Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Golgi-Associated Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMEM50A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM50A Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native conformation of extracellular loops. |
View TMEM50A Products |
| Gene Delivery | TMEM50A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Crucial for preserving multi-pass transmembrane structure. |
View TMEM50A Products |
| Benchmark Ab | Anti-TMEM50A Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View TMEM50A Products |
| Validator | TMEM50A siRNA Set For functional knockdown verification in oncology cell models. |
View TMEM50A Products |
| Related Target A | TMEM50B Homolog screening target to evaluate off-target toxicity and subfamily selectivity. |
View TMEM50B Products |
| Related Target B | EGFR Synergistic pathway partner; co-expression often correlates with aggressive glioblastoma phenotypes. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane conformation preservation | Lentivirus Premade Particles for stable cell line generation, enabling native cell-based flow cytometry and functional assays. |
| Subfamily counter-screening (TMEM50A vs TMEM50B) | Sequence-verified TMEM50B recombinant proteins and expression vectors available for cross-reactivity panels. |
| Lack of reliable positive controls | High-affinity Recombinant Benchmark Antibodies included in the catalog. |
| Target validation false positives | Sequence-verified siRNA pools for robust target knockdown and specificity validation. |
Live TMEM50A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TMEM50A (Transmembrane Protein 50A) is an emerging frontier in oncology and endoplasmic reticulum/Golgi-associated pathology. As a multi-pass transmembrane protein, TMEM50A plays a documented role in cell adhesion, organelle morphology, and tumor progression, particularly in glioblastoma and cervical cancers. The race for TMEM50A therapeutics is intensifying, with major players shifting focus from traditional mAbs to cell-based therapies and targeted delivery systems. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific extracellular loops and combination regimens to overcome resistance pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biotech Startups | Glioblastoma, Cervical Cancer | Conformation-specific binding (Requires Lentivirus for Stable Cell Lines) |
| siRNA / RNAi | RNAi Therapeutics Specialists | Solid Tumors, Metastatic Cancers | In vitro knockdown validation (Requires Validated siRNA Sets) |
| Small Molecule Inhibitors | Oncology-focused Pharma | Golgi-stress Related Disorders | Selectivity assays (Requires TMEM50A vs TMEM50B Mutant/WT Proteins) |